| |
Hazard ratio (95% CI)a
|
p Value*
|
|---|
|
No breastfeeding
|
1.0 (ref)
| |
|
Exclusive breastfeedingb
|
0.31 (0.12–0.67)
|
0.002
|
|
Nonexclusive breastfeedingb
|
0.59 (0.31–1.16)
|
0.126
|
|
Pre-pregnancy relapsesc
|
2.21 (1.23–3.69)
|
0.005
|
|
Use of DMT before pregnancy by 1 year
|
1.46 (0.90–2.38)
|
0.130
|
|
Pregnancy relapse
|
3.09 (1.68–5.67)
|
< 0.001
|
|
Use of postpartum DMTd
|
1.41 (0.71–2.58)
|
0.340
|
|
Age, (years)
|
0.92 (0.89–0.99)
|
0.016
|
|
Disease duration, (years)
|
1.12 (0.96–1.23)
|
0.437
|
|
Disabilitye
|
2.08 (1.72–3.41)
|
0.002
|
- CI confidence interval; DMT disease-modifying therapy; MS multiple sclerosis
- aCox proportional hazards model/ *Level of significance is set when the P-value < 0.05
- bReference group no breastfeeding
- cReference group 0–1 relapse in 2 years before pregnancy
- dTime-dependent covariate
- eReference group no MS-related disability at pregnancy onset
